

## Dr Janine Mansi's publications

### Publications

1. Coombes RC, Berger U, Mansi J, Redding H, Powles TJ, Neville AM, McKinna A, Nash AG, Gazet JC, Ford HT et al. (1986). Prognostic significance of micrometastases in bone marrow in patients with primary breast cancer. NCI Monogr 1: 51-3.
2. Mansi JL, Berger U, Easton D, McDonnell T, Redding H, Gazet J-C, McKinna A, Powles TJ, Coombes RC (1987) Bone marrow micrometastases in patients with primary breast cancer: an early predictor of bone marrow metastases. British Medical Journal 295, 1093-1097.
3. Berger U, Mansi JL, Wilson P, Coombes RC (1987) Detection of estrogen receptor in bone marrow from patients with metastatic breast cancer. Journal of Clinical Oncology 5, 1779-1782.
4. Mansi JL, Selby PJ, Carter R, Powles R, McElwain TJ (1987) Granulocytic sarcoma: a diagnosis to be considered in unusual lymphoma syndromes. Postgraduate Medical Journal 62, 447-449.
5. Mansi JL, Berger U, Wilson P, Coombes RC, Shearer R (1988) The detection of tumour cells in bone marrow of patients with prostatic carcinoma. Journal of Urology 139, 545-548.
6. Mansi JL, Earl H, Powles TJ, Coombes RC (1988) Tests for detecting recurrent disease in the follow up of patients with breast cancer. Breast Cancer Research Treatment 11, 249-254.
7. Mansi JL, Mesker W, van Driel-Kulker AMJ, Ploem JS, Coombes RC (1988) Automated screening of bone marrow smears for micrometastases. Journal of Immunological Methods 112, 105-111.
8. Mansi JL, Fisher C, Wiltshaw E, MacMillan S, King M, Stuart-Harris R (1988) A phase 1/11 study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. European Journal of Clinical Oncology 24(9), 1439-1443.
9. Berger U, Bettelheim R, Mansi JL, Easton D, Coombes RC (1988) The relationship between micrometastases in bone marrow and pathomorphological features of the primary tumour in breast cancer. American Journal of Clinical Pathology 90, 1-6.
10. Mansi JL, Hanks GW (1989) Drainage of malignant effusions. The Lancet i: 43.
11. Mansi JL, Berger U, McDonnell T, Gazet J-C, Rayter Z, Coombes RC (1989) The fate of micrometastases in primary breast cancer. Journal of Clinical Oncology 7, 445-449.
12. Mansi JL, Smith IE, Walsh G, A'Hern R, Sinnott HD, Trott PA, Fisher C, McKinna JA (1989) Primary medical therapy in operable breast cancer. European Journal Cancer Clinical Oncology 25, 1623-1627.
13. Lawson CS, Mansi JL, Wiltshaw E (1989) Prolonged survival in patient with disseminated malignant teratoma in the presence of a persistently elevated serum alpha-fetoprotein level. Cancer 63, 804-806.

14. Glaholm J, Leach MO, Collins D, Mansi JL, Sharp J, Madden A, Smith IE, McCready VR (1989) In vivo <sup>31</sup>P magnetic resonance spectroscopy for monitoring the treatment response of human breast carcinoma. *Lancet* ii, 1326-1327.
15. Mansi JL, Ramachandra S, Wiltshaw E, Fisher C (1990) Endometrial stromal sarcomas. *Gynaecologic Oncology* 26, 113-118.
16. Hawkins R, Wiltshaw E, Mansi JL (1990) Ifosfamide with and without adriamycin in advance uterine sarcomas. *Cancer Chemotherapy Pharmacology* 26, 26-29.
17. Selby P, Patel P, Milan S, Meldrum M, Mansi JL, Mbidde E, Bradam M, Perren T, Forgeson G, Gore M, Smith IE, McElwain TJ (1990) Ch1VPP combination chemotherapy or Hodgkin's disease: long term results. *British Journal of Cancer* 62, 279-285.
18. Dowsett M, Mehta A, Mansi JL, Smith IE (1990) A dose-comparative endocrine-clinical study of leuporelin in premenopausal breast cancer patients. *British Journal of Cancer* 62, 834-837.
19. Glaholm J, Collins D, Mansi JL, Sharp JC, Leach MO, McCready VR, Smith IE, Powles T, Hind AJ (1990) The importance of signal localisation and measurement of absolute metabolite changes when monitoring the treatment response of human breast carcinoma with in-vivo <sup>31</sup>P NMR spectroscopy. *Tumour Diagnostik* pp 158-164.
20. Bell JBG, Millar BC, Monets-Boringa A, Joffe JK, Cunningham D, Mansi JL, Treleaven J, Viner C, McElwain TJ (1990) Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone. *Haematology Oncology* 8: 347-353.
21. Adshead F, de Graeff A, Mansi JL, Thomas M, Smith IE (1991) Small cell carcinoma of the prostate: implications for management. *British Journal of Urology* ii, 217-219.
22. Newell DR, Mansi JL, Hardy J, Button D, Jenns K, Smith IE, Picollo R, Catanese B (1991) The pharmacokinetics of oral lonidamine in breast and lung cancer patients. *Seminars in Oncology* 18, 11-17.
23. Talbot DC, Smith IE, Mansi JL, Judson I, Calvert AH, Ashley SE (1991) Anthrapyrazole C1941: a highly active new agent in the treatment of advanced breast cancer. *Journal of Clinical Oncology* 9, 2141-2147.
24. Jodrell D, Smith IE, Mansi JL, Pearson MC et al (1991) A randomised comparative trial of mitozantrone, methotrexate, mitomycin C (MMM) and cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in the treatment of advanced breast cancer. *British Journal of Cancer* 63, 794-798.
25. Mansi JL, de Graeff A, Newell DR, Glaholm J, Button D, Leach MO, Payne G, Smith IE (1991) A phase II clinical and pharmacokinetic study of lonidamine in patients with advanced breast cancer. *British Journal of Cancer* 64, 593-597.
26. Mansi JL, Coombes RC (1991) Treatment of Metastatic Disease. *Diagnostic Oncology* 1, 161-167.
27. Hickish TF, Purvies H, Mansi JL, Soukop M, Cunningham D (1991) Molecular monitoring of low grade non-Hodgkin's lymphoma by gene amplification. *British Journal of Cancer* 64, 1161-1163.
28. Mansi JL, Easton D, Berger U, Gazet J-C, Ford HT, Dearnaley D, Coombes RC (1991) Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years follow up. *European Journal of Cancer* 27, 12, 1552-1555

29. Nicholson S, Evans C, Mansi JL (1992) Ondansetron in intractable nausea and vomiting. *The Lancet*: 339: 490.
30. Harding M, Selby P, Gore M, Perren T, Treleavan J, Mansi JL et al (1992) High dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's disease. *European Journal of Cancer* 28: 1396-1400
31. Mansi JL, da Costa F, Viner C, Judson I, Gore M, Cunningham D (1992) High dose busulphan in patients with myeloma. *Journal of Clinical Oncology* 10: 1569-1573.
32. Mansi JL, Ellis E, Viner C, Mundy J, Smith T, Millar J, Milan S, Gore M, Cunningham D (1992) Gut protection by cyclophosphamide 'priming' in patients receiving high dose melphalan -the effect of drug scheduling. *Cancer Chemotherapy Pharmacology* 30: 149-151.
33. Wasan H, Mansi JL, Benjamin S, Powles R, Cunningham D (1992) Myeloma and benign intracranial hypertension: a new association. *British Medical Journal* 304: 685.
34. Leach MO, Glaholm J, Findlay M, Cunningham D, Mansi JL, Collins D, Payne G S, McCready 8VR (1992) 19F clinical NMR spectroscopy in colorectal cancer: monitoring low level 5FU infusion therapy and the metabolic effects of additive alpha-interferon in advanced radiation therapy tumour response monitoring and treatment planning. Ed. Breit. Springer-Verlag, Berlin Heidelberg. pp. 218.
35. Mansi JL (1992) Ch1VPP: Reducing Toxicity in the Treatment of Hodgkin's Disease. *European Journal of Cancer* 28A: 8/9, 1411-1413.
36. Schofield JB, Mansi JL, Camplejohn RS, Lane DP, Fisher C (1992) Proliferating cell nuclear antigen and S phase fraction in endometrial stromal sarcoma. *J Clin Pathol* 45: 664-667.
37. Evans TRJ, Mansi JL, Glees JP (1993) Case Report: Response of metastatic anal carcinoma to single agent carboplatin. *Clinical Oncology* 5: 57-58.
38. Mansi JL, Evans TRJ, Smith A, Oakley C, Wastnage R, Dalglish AG (1993) Should we be using 5HT3 antagonists as first line antiemetic therapy in cisplatin-based chemotherapy? *Annals of Oncology* 4 (5): 433-434.
39. Moskovic EC, Mansi JL, King DM, Murch CR, Smith IE (1993) Mammography in the assessment of response to medical treatment of large primary breast cancer. *Clinical Radiology* 47: 339-344.
40. Findlay MPN, Leach MO, Cunningham D, Collins DJ, Payne GS, Glaholm J, Mansi JL, McCready VR (1993) The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: A pilot study. *Annals of Oncology* 4 (7): 597-603.
41. Hickish T, Roldan A, Cunningham D, Mansi JL, Ashley A, Nicolson V, Gore ME, Catovsky D, Smith IE (1993) EPIC: an effective low toxicity regimen for relapsing lymphoma. *British Journal of Cancer* 68 (3): 599-604.
42. Mansi JL, Cunningham D, Viner C, Ellis E, Meldrum M, Milan S, Gore M (1993) Repeat administration of high dose melphalan in relapsed myeloma. *Br J Cancer* 68 (5): 983-987.
43. Hill M, Cunningham D, Roldan A, MacVicar D, Husband J, McCready R, Mansi JL, Hickish T (1993) The role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. *J Clin Oncol* 11: 2273-2279.
44. Maher EJ, Hopwood P, Girling DJ, Macbeth FR, Mansi JL, Radstone DJ (1993) Measurement of outcome in palliative oncology. *Journal of Cancer Care*.

45. Seymour MT, Mansi JL, Gallagher CJ, Wiltshaw E, Harper PG, Evans TRJ, Edmonds PM, Slevin ML (1994) Protracted oral etoposide in epithelial ovarian cancer: A phase-II study in patients with relapsed or platinum-resistant disease. *Br J Cancer* 69: 191-195.
46. Kedar RP, Cosgrove DO, Smith IE, Mansi JL, Bamber JC (1994) Breast Carcinoma: Measurement of Tumor Response to primary medical therapy with Color Doppler Flow Imaging. *Radiology* 190: 825-830.
47. Evans TRJ, Mansi JL, Bull R, Fallowfield ME, Bevan DH, Harmer CL, Dalgleish AG (1994) Eosinophilic Folliculitis Occurring after Bone Marrow Autograft in a Patient with Non-Hodgkin's Lymphoma. *Cancer*, 73: 2512-2514.
48. Findlay M, Cunningham D, Norman A, Mansi JL, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H, Carter R and Hill A (1994). A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). *Annals of Oncology* 5: 609-616.
49. McCormick C, Philip E, Mansi JL, Livni N, McCarthy K (1994). Clonal analysis of three morphologically distinct lymphomas occurring in the same patient. *Journal of Clinical Pathology* 47: 1038-1042.
50. Cunningham D, Hill ME, Milan S, Mansi JL, Smith IE, Catovsky D, Gore M, O'Brien MER, Nicolson M, Hickish T (1994) Veep chemotherapy for adult Hodgkin's Disease - Assessment of efficacy and gonadal and cardiac toxicity. *Journal of Haematology* 84: 162.
51. Evans TRJ, Mansi JL, Bevan DH, Dalgleish AG, Harmer CL (1995) Case report: Primary non-Hodgkin's Lymphoma of the thyroid with bone marrow infiltration at presentation. *Clin Oncol* 7: 54-55.
52. Rayter Z, Leicester RJ, Mansi JL (1995) Adjuvant therapy for colorectal cancer. *Ann. R. Coll. Surg. Engl.* 77: 81-84.
53. Gore ME, Earl HM, Cassidy J, Tattersall M, Mansi J, Seymour L, Spiers J, Azab M (1995) A Phase II study of Tomudex in relapsed epithelial ovarian cancer. *Annals of Oncology* 6: 724-725.
54. Hill ME, Milan S, Cunningham D, Mansi JL, Smith IE, Catovsky D, Gore ME, Zulian GB, Selby PJ, O'Brien MER, Hickish T, Nicolson MC (1995) Evaluation of the efficacy of vincristine, epirubicin, etoposide and prednisolone (VEEP) in adult Hodgkin's Disease with assessment of gonadal and cardiac toxicity. *J. Clin. Oncol* 13 (2): 387-395.
55. Evans TRJ, Mansi JL (1995) Oesophageal varices: a potentially fatal complication of liver metastases. *European Journal of Surg. Oncology* 21: 204-205
56. Smyth JF, Hardcastle JD, Denton G, Alderson D, Grace RH, Mansi JL, Yosef HMA, Nordle Ö, Lauri H, Wählby S (1995) Two Phase III trials of Tauromustine (TCNU) in advanced colorectal cancer. *Annals of Oncology* 6:948-949.
57. Evans TRJ, Harper CL, Beveridge IG, Wastnage R, Mansi JL (1995) A randomised study to determine whether routine intravenous magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continuous infusion 5-fluorouracil. *European Journal of Cancer* 13A(2): 174-178.
58. Highley MS, Momerency G, Van Cauwenberghe K, Van Oosterom A T, de Bruijn E A, Blake P, Mansi JL, Harper PG (1995) The formation of Chloroethylamine and 1, 3 Oxazolidine-2-one following Ifosfamide administration in humans. *Drug Metabolism and Disposition* 23(3): 433-437.

59. Gogas H, Mansi JL (1996) New drugs. The Anthrapyrazoles. *Cancer Treatment Reviews* 21: 541-552.
60. Harper CL, Evans TRJ, Mansi JL (1996) An unusual presentation of Hodgkin's Disease. *Oncology Reports* 3(2): 273-275.
61. Harper CL, Lofts FJ, Otter M, Mansi JL (1996) Prostate-specific antigen (PSA) immunohistochemistry in the presence of a normal serum PSA as an aid to the diagnosis of adenocarcinoma of unknown primary site. *British Journal of Hospital Medicine* 55(6): 367-368.
62. Evans TRJ, Lofts FJ, Mansi JL, Glees JP, Dalglish AG, Knight MJ (1996) A Phase II study of continuous Infusion 5-Fluorouracil with Cisplatin and Epirubicin in inoperable pancreatic cancer. *British Journal of Cancer* 73: 1260-1264.
63. Mazucco RA, Maxwell RJ, Howells SL, Gogas H, Mansi JL, Griffiths JR (1996) Evaluation of artificial neural networks to distinguish <sup>1</sup>H NMR spectra of human blood plasma. *International Society for Magnetic Resonance in Medicine* (2): 1170.
64. Evans TRJ, Mansi JL, Adam EJ (1996) Primary isolated epithelioid hemangioendothelioma of a lumbar vertebra. *Oncology Reports* (3): 751-752.
65. Hutchison G, Mansi JL (1996) Cancer care in the community: a collaborative approach. *Journal of Cancer Care* (5): 93-95.
66. Evans TRJ, Mansi JL, Bevan DH (1996) Trousseau's syndrome in association with ovarian carcinoma. *Cancer* 77(12): 2544-499.
67. Lofts FJ, Evans TRJ, Wastnage R, Mansi JL (1996) Magnesium supplements with cisplatin chemotherapy. *European Journal of Cancer* 32A: 556-557.
68. Abdul-Rahman ZH, Gogas HJ, Tooze JA, Anderson B, Mansi JL, Sacks NP, Finlayson CA (1996) T-cell lymphoma in Hashimoto's thyroiditis. *Histopathology* 29 455-459.
69. Bataille, V, Cunningham D, Mansi JL, Mortimer P (1996) Inflammation of solar keratoses following systemic 5-Fluorouracil. *British J of Dermatology* 135(3): 478-480.
70. Mansi, JL (1996). Adjuvant treatment in high-risk breast cancer. *British J of Hospital Medicine* 56 (2-3): 112.
71. Lofts FJ, Evans TRJ, Mansi JL, Glees JP, Knight MJ (1997) Bile duct stents: Is there an increased rate of complications in patients receiving chemotherapy? *European Journal of Cancer* 33(2): 209-213.
72. Webb A, Cunningham D, Howard Scarffe J, Harper P, Norman A, Joffe JK, Hughes M, Mansi JL, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M (1997) Randomized trial comparing Epirubicin, Cisplatin and Fluorouracil versus Fluorouracil, Doxorubicin, and Methotrexate in Esophagogastric Cancer. *Journal of Clinic Oncology* 15(1): 261-267.
73. Harwood CA, Lofts F, Mansi JL, Glees JP, Marsden RA (1997) Bizarre gyrate erythema associated with malignant thymoma *British Journal of Dermatology* 136(1): 144-145.
74. Evans TRJ, Mansi JL, Morgan DAL, Gyi KM, Banham SW, Milroy R (1997) A Phase II study of Vinorelbine in patients with advanced non-small cell lung cancer. *Oncology Reports* 4: 639-642.
75. Gogas H, Lofts FJ, Evans TRJ, Millard FJC, Wilson R, Mansi JL (1997) Outpatient treatment with epirubicin and oral etoposide in patients with small cell lung cancer. *British Journal of Cancer* 76: 639-642.

76. Fox SB, Leek RD, Bliss J, Mansi JL, Gusterson B, Gatter KC, Harris AL (1997) Association of tumour angiogenesis with bone marrow micrometastases in breast cancer patients. *Journal of the National Cancer Institute* 89: 1044-1049.
77. Gogas H, Lofts FJ, Evans TRJ, Daryanani S, Mansi JL (1998) Are serial measurements of CA19.9 useful in productive response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas. *British Journal of Cancer* 77: 325-328.
78. Hardy J, Ling J, Mansi J, Isaacs R, Bliss J, A'Hern R, Blake P, Gore M, Shepherd J, Hanks G (1998) Pitfalls in placebo-controlled trials in palliative care: dexamethasone for the palliation of malignant bowel obstruction. *Palliative Medicine* 1998; Nov.12(6): 437-442.
79. Gore M, Mainwaring P, A'Hern R, MacFarlane V, Slevin M, Harper P, Osborne R, Mansi J, Blake P, Wiltshaw E, Shepherd J. (1998). Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. *Journal of Clinical Oncology* 16(7): 2426-2434.
80. Primrose JN, Bleiberg H, Daniel F, Van Belle S, Mansi JL, Seymour M, Johnson PW, Neoptolemos JP, Baillet M, Barker K, Berrington A, Brown PH, Millar AW, Lynch KP (1999). Marimastat in recurrent colorectal cancer: Exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. *British Journal of Cancer* 79(3-4): 509-14.
81. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi JL, Leahy M, Hill A, Oates J, Rao S, Nicholson M, Hickish T (1999) Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomised trial. *British Journal of Cancer* 80(1/2): 269-272.
82. Mitchell PLR, Al-Nasiri N, A'Hern R, Fisher C, Horwich A, Pinkerton CR, Shepherd JH, Gallagher C, Slevin M, Harper P, Osborne R, Mansi JL, Oliver T, Gore ME (1999) Treatment of nondysgerminomatous ovarian germ cell tumors - an analysis of 69 cases. *Cancer* 85: 2232-2244.
83. Mansi JL, Gogas H, Bliss JM, Gazet J-C, Berger U, Coombes RC (1999) Outcome of primary breast cancer patients with micrometastases:- a long-term follow up study. *The Lancet* 354: 197-202.
84. Lofts FJ, Gogas H, Mansi JL (1999). Management of adenocarcinoma of unknown primary with a 5FU/cisplatin chemotherapy regimen. *Annals of Oncology* 1999; Nov 10(11): 1389-1392.
85. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. (2000). Bisphosphonates induce apoptosis in human breast cancer cell lines. *British Journal of Cancer*, 2000; Apr; 82(8), 1459-68.
86. Bretherton-Watt D, Given-Wilson R, Mansi JL, Thomas V, Carter N, Colston KW (2001) Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. *British Journal of Cancer* 2001; July 20:85(2), 171-175.
87. Smith IE, O'Brien MER, Talbot DC, Nicolson MC, Mansi JL, Hickish TF, Norton A, Ashley S. (2001). Duration of chemotherapy in advanced non-small cell lung cancer: a randomised trial of three versus six courses of mitomycin, vinblastine and cisplatin. *Journal of Clinical Oncology* 2001, Mar 1; 19(5), 1336-1343.
88. Leonard R, Hardy J, van Tienhoven G, Houston S, Simmonds P, David M, Mansi J (2001). Randomized double-blind placebo-controlled multicentre trial of 6% Miltefosine Solution, a Topical Chemotherapy in Cutaneous Metastases

- from Breast Cancer. *Journal of Clinical Oncology* 2001 Nov 1; 19(21), 4150-4159
89. Evans TRJ, Colston KW, Lofts FJ, Cunningham D, Anthoney DA, Gogas H, de Bono JS, Hamberg KJ, Skov T, Mansi JL (2002). A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. *British Journal of Cancer* Mar 4; 86(5), 680-685.
  90. Senaratne SG, Mansi JL, Colson KW (2002). The bisphosphonate zoledronic acid impairs Ras membrane localisation and induces cytochrome c release in breast cancer cells. *British Journal of Cancer* 2002; May 6: 86(9), 1479-1486.
  91. Cameron DA, Anderson A, Toy E, Evans TJ, Le Vay, Kennedy ICS, Grieve RJ, Perren TJ, Jones A, Mansi J, Crown J, Leonard RCF (2002). Block sequential Adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer? *British Journal of Cancer*; 87, 1365-1369.
  92. Pickering LM, Mansi JL. (2002). The evolving use of bisphosphonates in breast cancer. *International Breast Cancer Reviews* ,2,2-7
  93. Clemons M, Hamilton T, Mansi JL, Lockwood G, Goss PE (2003) Management of recurrent locoregional breast cancer: oncologist survey. *The Breast*, Oct;12(5):328-37.
  94. Guy M, Lowe LC, Bretherton-Watt DC, Mansi JL & Colston KW (2003). Approaches to evaluating the association of vitamin D receptor gene polymorphisms with breast cancer risk. *Recent Results in Cancer Research* 2003 Pub: Springer-Verlag. Vol 164:43-54 (review).
  95. Macdonald C, Michael A, Colson K, Mansi JL (2004). Heterogeneity of immunostaining for tumour markers in non-small cell lung carcinoma. *European Journal of Cancer* 2004; 40(3): 461-466.
  96. Palmieri C, Lam EW-F, Mansi J, Macdonald C, Shousha S, Madden P, Omoto Y, Sunter A, Warner M, Gustafsson J-A & Coombes RC (2004). The expression of ER $\beta$ cx in human breast cancer, and the relationship to endocrine therapy and survival. *Clin Cancer Research*, Apr 1;10(7):2421-8.
  97. Rodrigues LM, Stubbs M, Robinson SP, Newell B, Mansi J & Griffiths JR. (2004) The C-neu mammary carcinoma in Oncomice®; characterisation and monitoring response to treatment with herceptin by magnetic resonance methods. *MAGMA*, 2004 Dec;17(3-6):260-70. Epub 2004 Dec 20
  98. Guy M, Lowe LC, Bretherton-Watt D, Mansi JL, Peckitt C, Bliss J, Given-Wilson R, Thomas V & Colston KW (2004). Vitamin D receptor gene polymorphisms and breast cancer risk. *Clin Cancer Res*. 2004 Aug 15;10(16):5472-5481.
  99. Smith IE, A'Hern RPA, Coombes GA, Howell A, Ebbs SR, Hickish TF, O'Brien MER, Mansi JL, Wilson CB, Robinson AC, Murray PA, Price CGA, Perren TJ, Laing RW & Bliss JM on behalf of the TOPIC Trial Group (2004). A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. *Annals of Oncology* 2004 May;; 15(5): 751-758.
  100. Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D. (2004) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community versus hospital bisphosphonate administration. *Br J Cancer*. 2005 May 23;92 (10):1869-76.
  101. Evans TRJ, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones A, Highley M,

- Leonard RC, Mansi JL, on behalf of the Anglo-Celtic Cooperative Oncology Group (2005) A phase III randomised trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group Study. *J Clin Oncol* 2005 May 1;23(13):2988-95.
102. Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Given Wilson R, & Colston KW . Circulating insulin-like growth factor-1 levels and breast cancer risk in a UK Caucasian population. In press as a short report in *BJC* 2005.
  103. Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Given Wilson R, & Colston KW (2005). Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. *Eur J Cancer*. 2005 May;41(8):1164-9. Epub 2005 Apr 14
  104. Lowe LC, Guy M, Brain H, Oades G, Mansi JL & Colston KW (2004). Linkage between vitamin D receptor polymorphism in a UK South-Asian population. In press: *Journal of Endocrinology* 2005.
  105. Polychronis A, Sinnott HD, Hadjiminas D, Singhal H, Mansi JL, Shivapatham D, Shousha S, Jiang J, Peston D, Barrett N, Vigushin D, Morrison K, Beresford E, Ali S, Slade MJ, Coombes RC (2005). Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase 11 randomised trial. *Lancet Oncol* 2005 Jun;6(6):357
  106. Townsend K, Banwell CM, Guy M, Colston KW, Mansi JL, Stewart PM, Campbell MJ, Hewison M. (2005) Autocrine metabolism of vitamin D in normal and malignant breast tissue. *Clin Cancer Res*. 2005 May 1;11(9):3579-86
  107. Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, Spooner DA, Agrawal RK, Fernando IN, Brunt AM, O'Reilly SM, Crawford SM, Rea D, Simmonds P, Mansi J, McAdam K, Stanley A, Harvey P, Foster E, Leonard RC, Twelves CJ for the NEAT Investigators and the SCTBG (2005). NEAT (National Epirubicin Adjuvant Trial) and SCTBG (Scottish Cancer Trials Breast Group) BR9601 phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF. Epirubicin and cyclophosphamide, methotrexate and fluorouracil as adjuvant therapy for early breast cancer. *N Engl J Med*. 2006 Nov 2;355(18):1851-62
  108. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, Cormier Y, Ellis Peter, Price A. Sawhney R, Davis M, Mansi J, Smith C, Vergidis D, Ellis Paul, MacNeil M, Palmer M. Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIB and IV non-small cell lung cancer (NSCLC). *J Clin Oncol*. 2005 Sep 20;23(27):6674-81
  109. Colston KW, Lowe LC, Mansi JL, Campbell MJ. Vitamin D status and breast cancer risk. *Anticancer Res*. 2006 Jul-Aug;26:26(4A):2573-80
  110. Banwell CM, MacCartney DP, Guy M, Miles AE, Uskokovic MR, Mansi J, Stewart PM, O'Neill LP, Turner BM, Colston KW, Campbell MJ. Altered nuclear receptor corepressor expression attenuates vitamin D receptor signalling in breast cancer cells. *Clin Cancer Res*. 2006 Apr 1;12(7 Pt 1):2004-13
  111. Janine L. Mansi<sup>1</sup>, Ann Yellowlees<sup>2</sup>, Julian Lipscombe<sup>3</sup>, Helena M. Earl<sup>4</sup>, David A. Cameron<sup>5</sup>, Robert E. Coleman<sup>6</sup>, Timothy Perren<sup>7</sup>, Christopher J. Gallagher<sup>8</sup>, Mary Quigley<sup>9</sup>, John Crown<sup>10</sup>, Alison L. Jones<sup>11</sup>, Martin Highley<sup>12</sup>, Robert C.F. Leonard<sup>13</sup>, T.R. Jeffery Evans<sup>14</sup> on behalf of the Anglo-Celtic Cooperative Oncology Group. Five-year outcome for women randomised in a Phase III trial comparing doxorubicin and cyclophosphamide with



doxorubicin and docetaxel as primary medical therapy in early breast cancer: An Anglo-Celtic Cooperative Oncology Group Study. *Breast Cancer Research and Treatment* 2010;22:787-794

112. R. Leonard, R Ballinger, D Cameron, P Ellis, L Fallowfield, M Gosney, L Johnson, LS Kilburn, A Makris, J Mansi, M Reed, A Ring, A Robinson, P Simmonds, G Thomas, JM Bliss. Adjuvant chemotherapy in older women (ACTION) study – what did we learn from the pilot phase? *Brit J Cancer* 2011; 105:1260-1266

## **Manuscripts in preparation**

1. Pickering LM, Mansi JL, Colston KW. Zoledronic acid impairs the adhesion of breast cancer cell lines to mineralised matrices.
2. Pickering LM, Senaratne SG, Mansi JL, Colston KW. The bisphosphonate zoledronic acid downregulates Ras signalling pathways in human breast cancer cell lines. *Clinical Cancer Research*.
3. Macdonald CD, Pickering LM, Mansi JL, Colston KW. Bisphosphonates induce apoptosis in lung cancer cell lines
4. Guy M, Lowe LC , Mansi JL, Peckitt C, Bliss J, Given Wilson R, Thomas V & Colston KW . Relationship between Vitamin D receptor gene polymorphisms and breast cancer recurrence and survival. .
5. Pickering LM, Mansi JL, Colston KW. HER2 overexpression confers relative resistance to the in vitor effects of bisphosphonates
6. SV Barrett, TRJ Evans, JL Mansi, D Cameron, RCF Leonard, T Perren, E Foster, M Rahilly, J Crown, J Curto, R Brown, on behalf of the Anglo-Celtic Co-operative Oncology Group.
7. Lisa Pickering, Janine L Mansi, Tim R Arnett and Kay W Colston. Breast cancer cell adhesion and invasion are abrogated by inhibition of protein prenylation; a laboratory study. *Breast Cancer Research*.
8. MS Highley, G Momerency, D Sawyers, EA De Bruijn, H Prenen, G Guetens, G De Boeck, AT Van Oosterom, JL Mansi, PR Blake, T Mant, RAA Maes and PG Harper. The neurotoxicity and pharmacokinetics of oral ifosfamide. To be submitted to *Clinical Cancer Research*.

## **Research participation resulting in published manuscripts (not exhaustive)**

- 1 Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003). A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. *N Engl J Med*. 2003 Nov 6; 349(19): 1793-802
- 2 Coombes RC, Hall E, Gibson LJ, Phil M, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, & Bliss JM for the Intergroup Exemestane Study (2004). A randomised trial of exemestane

- after 2 to 3 years of tamoxifen therapy in postmenopausal women with primary breast cancer. *N Eng J Med*; 350: 1081-92.
- 3 Howell A, Robertson JFR, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I & Osborne CK (2004). Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomised trial. *Journal of Clinical Oncology* 22: 1605 –1613.
  - 4 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. *Lancet*. 2005 Jan 1; 365(9453):60-2.
  - 5 Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase 111, randomised controlled trial. Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt C, Hall E, Bliss JM; TACT Trial Management Group; TACT Trialists. *Lancet* 2009 373: 1661-92
  - 6 azure study

## Chapters and editorials

1. Mansi JL, Powles TJ, Coombes RC (1987) The detection and evaluation of bone marrow micrometastases in primary breast cancer. In: *Fundamental Problems in Breast Cancer*. Eds. Patterson, AGH. pp 299-301.
2. Mansi JL and Smith IE (1989) Endocrine therapy for breast cancer: mechanism and new approaches. *Cancer Topics* 7: 57-59.
3. Mansi JL and Coombes RC (1989) The role of monoclonal and polyclonal antibodies in assessing risk in breast cancer. In: *High Risk Breast Cancer*. Eds: Ragaz J, Ariel IE. Springer-Verlag, Heidelberg pp 275-295.
4. Mansi JL and Hanks GW (1989) Management of symptoms in advanced cancer. *Update* July pp 82-94.
5. Mansi JL (1990) Chemotherapy of advanced breast cancer - current approaches. *Current Medical Literature. Breast Cancer*, Royal Society of Medicine 2: 35-37.
6. Maraveyas A, Mansi JL. (1999) CA19-9 in the prediction of response to systemic treatments in inoperable carcinoma of the pancreas. *Tumour Marker Update* 11(2): 55-59
7. Maraveyas A and Mansi JL (2000) Management of side effects of adjuvant therapy including chemotherapy and endocrine effects. *Breast Cancer: Diagnosis and Management. European School of Oncology and Advanced Education Series*. Ed: Dixon JM
8. Pickering LM & Mansi JL (2002). The role of bisphosphonates in breast cancer management: Review article. *Current Medical Research and Opinions*, 2002 18(5): 284-295.
9. Mansi JL (2003) *Medical Therapy of Breast Cancer*. Joint Editor with Mr Z Rayter . Published by Cambridge University Press 9th January 2003.
10. Mansi JL. *Primary Medical Therapy in Breast Cancer*. Chapter 10 in *Medical Therapy of Breast Cancer*; Ed Rayter Z & Mansi JL. Cambridge University Press. (2003)

11. Bishop L, Dougherty L, Bodenham A, Mansi J, Crowe P, Kibbler C, Shannon M, Treleaven J. Guidelines on the insertion and management of central venous access devices in adults. *Int J Lab Hematol.* 2007 Aug;29(4):261-78, Review
12. Sarah Rudman, Mark Harries and Janine Mansi. Minimal residual disease, bone marrow micrometastases and the breast cancer “stem cell”, *Mediscript* Sept 2008, Vol 5; Issue 3; 53 – 58
13. Breast Cancer: Systemic Therapy. Janine Mansi Chapter in *Oxford Textbook of Medicine* 2010

### **Invited speaker (not exhaustive)**

1. Mansi JL. Detection and evaluation of bone marrow micrometastases in primary breast cancer. Ciba Geigy Bone Marrow Metastases Workshop, Sutton Coldfield, November 1985.
2. Mansi JL, Berger U, O'Connell T, Coombes RC. The prognostic significance of bone marrow micrometastases in patients with primary breast cancer. British Breast Group, ICRF, London, February 1987.
3. Mansi JL. The prognostic significance of bone marrow micrometastases in patients with primary breast cancer. University of Munich, February 1987.
4. Mansi JL, Berger U, O'Connell T, Coombes RC, Shearer R. The detection of tumour cells in bone marrow of patients with prostatic carcinoma using immunocytochemical techniques. British Prostate Group, Wolverhampton, May 1987.
5. Mansi JL. The detection of tumour cells in bone marrow patients with prostatic carcinoma using immunocytochemical techniques. Institute of Urology, November 1987.
6. Mansi JL. Adjuvant therapy in breast cancer. Association of Surgeons in Training, Guildford, October 1989.
7. Mansi JL. Advances in endocrine and chemotherapy in advanced breast cancer. Mammographica Symposia, Costa Rica, November 1989.
8. Mansi JL. Adjuvant chemotherapy in breast cancer. Mammographica Symposia, Costa Rica, November 1989.
9. Mansi JL. Endocrine therapy in advanced breast cancer. 3rd Palliative Care Course, Charing Cross Hospital, November 1989.
10. Glaholm J, Leach MO, Collins D, Mansi JL et al. In vivo localised <sup>31</sup>P spectroscopy of human breast carcinoma. International Mammographic Society, September 1989.
11. Mansi JL. Plenary lecture: Micrometastases in Primary Breast Cancer. National Congress with International Participation 1991 Athens, Greece.
12. Mansi JL. Chemotherapy in the 1990s. Oncology Symposium. The Royal Pharmaceutical Society of Great Britain, South West Metropolitan Branch, March 1995.
13. Mansi JL. Tumour Markers in Breast Cancer. Association of Clinical Pathologists National Scientific Meeting and 2nd Congress of the European Society of Clinical Pathology October 1997.
14. Mansi JL. Primary chemotherapy in operable breast cancer. Athens, October 1997.
15. Mansi JL. Chemotherapy for non-small cell lung cancer. Thoracic Society November 1997.

16. Mansi JL. Bone marrow micrometastases in primary breast cancer. Glasgow, January 1998.
17. Mansi JL. High dose chemotherapy in early breast cancer. East Kent Breast Group, December 1998.
18. Mansi JL. Non-small cell lung cancer – an update. Junior Oncology Club October 2000.
19. Mansi JL. Micrometastases in breast cancer. Minimal Residual Disease Symposium at the Hammersmith Hospital, 1999.
20. Mansi JL. New approaches in small cell lung cancer. 8th Hellenic Congress of Medical Oncology, Athens, March 1999.
21. Mansi JL. Management of locally advanced disease and metastatic breast cancer: definition and choice of systemic therapy. Breast Cancer 2000, (Hospital Medicine in association with British Journal of Nursing) London, April 2000.
22. Mansi, JL. Update in non-small cell lung cancer. Junior Oncology Club, 2000.
23. Mansi JL. Management of locally advanced disease and metastatic breast cancer: Definition and choice of systemic therapy. Breast Cancer 2001, Coventry, 2001.
24. Mansi JL. Primary chemotherapy in operable breast cancer. Breast Cancer 2002, London, February 2002.
25. Mansi JL. Adjuvant Chemotherapy and Endocrine Treatment for Breast Cancer. Postgraduate Certificate/Diploma in Breast Diagnosis, Module 5 Breast cancer treatment and palliative care. Faculty of Health and Social Care Sciences, St George's Hospital Medical School. June 2002.
26. Mansi JL (2003). Management of metastatic breast cancer. Breast Cancer Course, St George's Hospital, June 2003.
27. Mansi JL (2003). Management of adjuvant breast cancer. Regional Study Day Intermediate Distance Learning Breast Disease Course, September 2003, Royal College of Surgeons, London.
28. Mansi JL (2003). Treatment of metastatic breast cancer: current practice, future trials, what is new? Breast Cancer 2003, Institute of Physics, London, October 2003.
29. Mansi JL (2005). Management of metastatic breast cancer. St Raphael's Hospice.
30. Mansi JL (2005) National Diploma in Breast Cancer: metastatic trajectory and disease recurrence

### **Published oral and poster presentations (not exhaustive)**

1. Coombes RC, Berger U, Mansi JL, Redding H, Powles TJ, Neville AM, McKinna A, Nash AG, Gazet J-C, Ford HT, Ormerod M, McDonnell T (1986) The prognostic significance of micrometastases in the bone marrow of patients with primary breast cancer. NCI Monography 1, 51-53. oral
2. Mansi JL, Berger U, O'Connell T, Coombes RC. Repeat bone marrow aspirates in patients with primary breast cancer. British Association of Cancer Research, November 1986. oral
3. Mansi JL, Berger U, O'Connell T, Coombes RC, Shearer R. The detection of tumour cells in bone marrow of patients with prostatic carcinoma using immuno-cytochemical techniques. British Association of Cancer Research, December 1987. oral

4. Mansi JL, MacMillan S, Fisher C, Wiltshaw E. A phase I-II study of ifosfamide in combination with adriamycin in adult soft tissue sarcomas. British Association of Cancer Research, March 1988.poster
5. Mansi JL, Berger U, McDonnell T et al. The fate of micrometastases in primary breast cancer. European Society of Medical Oncology, 1988.poster
6. Mansi JL, Smith IE, Walsh G, Sinnott D, McKinna JA. Primary medical therapy for operable breast cancer. Association of Cancer Physicians, April 1989.oral
7. Mansi JL, Smith IE, Walsh G, Sinnott D, McKinna JA. Primary medical therapy for operable breast cancer. ECCO, September 1989.poster
8. Jodrell DI, Mansi JL, Ashley SE et al. A randomised comparison of mitoxantrone, methotrexate and mitomycin C (MMC) and cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first line chemotherapy (CT) for advanced breast cancer. ECCO, September 1989.poster
9. Mansi JL, Smith IE, Talbot D, Judson I, Calvert H (1990) A phase II study of anthracycline C141. A highly active new drug against advanced breast cancer. British Journal of Cancer 62: 498 (Abs).oral
10. Cunningham D, Cahn A, Menzies-Gow N, Rosin RD, Guillelo PJ, Dudley HDF, Mansi JL. (1990) Cisplatin, epirubicin and 5-fluorouracil (CEF) has significant activity in advanced gastric cancer. British Journal of Cancer 62: 498 (Abs).oral
11. Mansi JL. Navelbine in combination chemotherapy in advanced breast cancer. UICC, August 1990. oral
12. Newell DR, Mansi JL, Hardy J, et al. The pharmacokinetics of oral lonidamine (L) in breast and lung cancer patients. UICC, Hamburg 1990.oral
13. Glaholm J, Collins D, Mansi JL. et al. The importance of signal localisation and measurement of absolute metabolite changes when monitoring the treatment response of human breast carcinoma with in-vivo <sup>31</sup>P NMR spectroscopy. Radioactive Isotopes in Clinical Medicine Research. Badgastein, January 1990.oral
14. Mansi JL, Smith I, Selby P, Cunningham D. VEEP: A new regimen in Hodgkin's Disease. European Society of Medical Oncology 1990 Copenhagen.oral
15. Mansi JL et al. ECF: A highly active regimen in gastric carcinoma. European Society of Medical Oncology 1990 Copenhagen.oral
16. de Graeff A, Mansi JL, Newell DR, Smith IE. A phase II study of lonidamine in patients with advanced breast cancer. ECCO, September 1989.poster
17. Hawkins R, Wiltshaw E, Mansi JL. Ifosfamide with and without adriamycin in advanced uterine sarcomas. ECCO 5 Congress 1989. Satellite Symposium "Ifosfamide in Gynaecological Tumours".poster
18. Newell DR, Mansi JL, Hardy J et al. The pharmacokinetics of oral lonidamine in breast and lung cancer patients. British Association of Cancer Research, 1990.poster
19. Newell DR, Mansi JL, Hardy J et al. The pharmacokinetics of oral lonidamine in breast and lung cancer patients. American Association of Cancer Research 1990.poster
20. Mansi JL, Easton D, Coombes RC. Micrometastases in primary breast cancer. American Association of Cancer Research 1990 poster
21. Hickish T, Purves H, Mansi JL, McElwain TJ, Cunningham D. The clinical utility of molecular techniques in B cell malignancy. Cancer Research Campaign, St George's Hospital, 1990.poster
22. Mansi JL, de Graeff A, Button D, Smith I E. A phase II study of lonidamine in patients with advanced breast cancer. UICC, Hamburg 1990.poster

23. Smith IE, Mansi JL, Walsh G et al. Primary medical therapy for operable breast cancer. UICC, Hamburg 1990.poster
24. Findlay M, Mansi JL, Hill A, Leach MD, Glaholm J, Ford HT, Payne G, Collines D, Cunningham D. (1991) Modulation of continuous low dose (300mg/m<sup>2</sup>) 5-fluorouracil (5FU) with  $\alpha$ -interferon colorectal cancer – clinical results and metabolic monitoring of 5FU using <sup>19</sup>F MRI spectroscopy. European Journal of Cancer 27 (2).oral
25. Cunningham D, Findlay M, Milan S, Millar B, Mansi JL, Viner C, Malpas J, Gore MG, McCallum P, Johnston P. (1991) Induction, intensification and maintenance of remission in myeloma -the roles of verapamil, high dose melphalan (HDM) and interferon. European Journal of Cancer 27 (2).oral
26. Findlay M, Mansi JL, Ford HT, Nash HT, Cunningham D. (1991) Epirubicin, cisplatin and 5-fluorouracil (ECF) is highly effective in advanced gastric cancer. European Journal of Cancer 27 (2).oral
27. Hickish T, Purvies H, Mansi JL, Soukop M, Cunningham D. (1991) Molecular monitoring of low grade non-Hodgkin's lymphoma by gene amplification. European Journal of Cancer 27 (2).oral
28. Roldan A, Mansi JL, Hickish T, Gore ME, Smith IE, Cunningham D. (1991) EPIC- an effective regimen for relapsing lymphoma with low toxicity. European Journal of Cancer 27 (2).oral
29. Cunningham D, Mansi JL, Ford HT, Nash NT, Menzies-Gow N. Epirubicin, cisplatin and 5-fluorouracil (ECF) is highly effective in advanced gastric cancer. Proceedings of ASCO 1991:10 (412) pp136 poste
30. Mansi JL, Smith IE, Selby PJ, Cunningham D. VEEP: a new chemotherapy regimen for Hodgkin's Disease. British Journal of Cancer 1991: 63 (supp XIII).poster
31. Cunningham D, Mansi JL, Hill A, Leach MO, Glaholm J, Ford HT, Payne G, Collins D. Modulation of continuous low dose (200-300 mg) 5-fluorouracil (5-FU) with  $\alpha$ -interferon (Intron A) in colorectal cancer - clinical results and the use of <sup>19</sup>-F NMR spectroscopy for non-invasive metabolic monitoring of 5-fluorouracil. British Journal of Cancer 1991: 63 (supp XIII).poster
32. Findlay M, Mansi JL, Ford HT, Nash AT, Menzies-Gow N, Cunningham D. Epirubicin, cisplatin and 5-fluorouracil (ECF) is highly effective in advanced gastric cancer. British Journal of Cancer 1991: 63 (supp XIII)poster.
33. Findlay M, Da Costa F, Mansi JL, Viner C, Millar B, Bell J, Jusdon I, Gore ME, McCallum P, Johnstone P, Cunningham D. High dose busulphan in patients with myeloma. European Journal of Cancer 1991: 27 (2).poster
34. Findlay M, Mansi JL, Viner C, Ellis E, Meldrum M, Milan S, Gore ME, Cunningham D. Repeat administration of high dose melphalan (HDM) in relapsed myeloma. European Journal of Cancer 1991: 27 (2).poster
35. Judson IR, Talbot DC, Smith IE, Graham MA, Tierney KL, Mansi JL, Calvert AH, Foster BJ. Cardiotoxicity of the anthracycline C141, not due to free radical formation. AACR 1991.poster
36. Cunningham D, Mansi JL (1991) Preliminary experience with VEEP (vincristine, epirubicin, etoposide and prednisolone) in Hodgkin's Disease. Pharmacorubicin Update 90 Symposium 44-45.poster
37. Jones A, Wiltshaw E, Harper P, Slevin M, Shepherd J, Mansi JL, Blake P, Tan S, Gore M. (1992) A randomised study of high versus conventional dose carboplatin for previously untreated ovarian cancer. British Journal of Cancer 64 : suppl. XIV.oral

38. Findlay M, Leach M, Glaholm J, Nicolson M, Mansi JL, Collins D, Norman A, Payne G, McCready V, Cunningham D. (1992) Monitoring interferon (Intron A) modulation of 5-fluorouracil in patients with colorectal cancer using <sup>19</sup>F magnetic resonance spectroscopy: correlation with clinical effects and implications for further clinical trials. *Proceedings of ASCO* 11: 170.oral
39. Evans TRJ, Glees JP, Knight MJ, Leceister RJ, Fiennes A, Mansi JL. The use of a new combination chemotherapy: Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) in upper gastrointestinal (GI) tumours. *ESMO Annals of Oncology* 1992 52: 14.poster
40. Evans TRJ, Millard FJC, Sanders KB, Coombes RC, Mansi JL. A randomised trial of 3 versus 6 cycles of combination chemotherapy with etoposide and epirubicin (EE) in small cell lung cancer (SCLC). *ESMO Annals of Oncology* 1992 154: 39.poster
41. Leach MO, Findlay M, Glaholm J, Mansi JL, Collins D, Payne G, McCready VR, Cunningham D. 5FU Modulation and metabolism in colonic cancer monitored by <sup>19</sup>-F MRS. *Radiology and Oncology* 1993.oral
42. Highley M, Harper P, Tomlin I, Morgan M, Gore M, Mansi JL, Gregory W, Sawyers D, Schwartz M, Mant T, Blake P. The treatment of advanced and recurrent cervical cancer with oral Ifosfamide. *British Gynaecological Cancer Society, Cambridge* 1993.oral
43. Findlay M, Norman A, Mansi JL, Nicolson N, Hickish T, Nicolson V, Carrington T, Nash A, Sacks N, Ford R, Carter R, Hill A, Cunningham D. (1993) A Phase II study in advanced gastric cancer using epirubicin and cisplatin in combination with continuous infusion 5-FU (ECF). *British Journal of Cancer* 4.3 pp15.oral
44. Cunningham D, Powles R, Malpas JS, Milan S, Meldrum M, Viner C, Montes A, Hickish T, Nicolson M, Johnson P, Mansi JL, Trevalan, Raymond J, Gore ME. (1993) A randomised trial of maintenance therapy with intron-A following high dose melphalan and ABMT in myeloma. *British Journal of Cancer* 11.7 pp30.oral
45. Hutchison G and Mansi JL. (1993) Needs and problems experienced by patients with gastrointestinal cancer receiving continuous ambulatory chemotherapy. *European Journal of Cancer* 29A (Suppl 6):1413.oral
46. Highley M, Harper P, Tomlin I, Morgan M, Gore M, Mansi JL, Gregory W, Sawyers D, Schwartz M, Mant T, Blake P. Phase II trial of oral ifosfamide in advanced recurrent cervical cancer. *British Journal of Cancer* 1993 P21: 36.poster
47. Hill ME, MacVicar D, Milan S, Husband J, Hickish T, McCready R, Mansi JL, Cunningham D. The role of magnetic resonance imaging in predicting relapse in residual masses after treatment of cancer. *British Journal of Cancer* 1993 P138: 65.poster
48. Hill ME, Mansi JL, Milan S, Wickens L, Hickish T, Smith IE, Cunningham D. VEEP Chemotherapy for Hodgkin's Disease - a regimen designed to reduce sterility and second malignancies. *British Journal of Cancer* 1993 P34: 39.poster
49. Evans TRJ, Harper C, Beveridge IG, Wastnage R, Dalgleish AG, Mansi JL. The use of routine magnesium supplements with cisplatin-containing chemotherapy regimen. *European Journal of Cancer* 29A (Supplement 6) S107, 1993.poster
50. Hill ME, Milan S, Cunningham D, Mansi JL, Smith IE, Catovsky D, Gore ME, Zulian GB, Selby PJ, O'Brien MER, Hickish T, Nicolson MC (1994) Evaluation of the efficacy of vincristine, epirubicin, etoposide and prednisolone (VEEP) in adult Hodgkin's Disease with assessment of gonadal and cardiac toxicity. *Annals of Oncology* 1994 5(supp 8): 133.oral

51. Jatoi I, Mansi JL, Bliss JM, Baum M, Coombes RC. Influence of menopause on bone marrow micrometastases. UICC 1994.poster
52. Highley M, Harper P, Sawyers D, Momerency G, De Bruijn E, Schwartz M, Gregory W, Van oosterom A, Van Cauwenberghe K, Mansi JL, Mant T, Blake P. The neurological effects of oral Ifosfamide. *Annals of Oncology* 1994 5(Supp 8): 181.poster
53. Highley M, Parnis F, Harper P, Sawyers D, Schwartz M, Gregory W, Mansi JL, Mant T, Blake P. Neurological changes after Ifosfamide administration. 21st Annual Scientific Meeting - Clinical Oncological Society 1994.poster
54. Cunningham, D, Hill, ME, Milan, S, Mansi, JL, Smith, IE, Catovsky, D, Gore, M, O'Brien, MER, Nicolson, M, Hickish, T. VEEP chemotherapy for adult Hodgkins Disease - assessment of efficacy and gonadal and cardiac toxicity. *Blood* 1994 84(10 S1): P A162.poster
55. Evans TRJ, Lofts FJ, Mansi JL, Glees JP, Knight MJ. A phase II study of continuous infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. *British Journal of Cancer* 1995 P98: 48.poster
56. Lofts FJ, Wastnage R, Evans TRJ, Mansi JL. Absence of symptomatic hypomagnesaemia in patients receiving half normal magnesium supplements with cisplatin chemotherapy. *British Journal of Cancer* 1995 P84: 45.poster
57. Lofts FJ, Evans TRJ, Knight MJ, Mansi JL. Retrospective analysis of complications related to biliary stents in patients receiving chemotherapy. *British Journal of Cancer* 1995 P86: 45.poster
58. Oakley, CM, Mansi, JL. The implementation of a home chemotherapy service - a collaborative project between hospital and community. *European Journal of Cancer* 1995 31A (S5): P1324.poster
59. Highley, M, Momerency, G, Vancauwenberghe, K, Vanoosterom, A, Debruijn, E, Maes, R, Blake, P, Mansi, JL, Harper, P. Hydrolysis of Ifosfamide to Chloroethylamine. *European Journal of Cancer* 1995 31A (S5): P941.poster
60. Webb A, Cunningham D, Howard Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi JL, Findlay M, Hill A, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M. (1996) A randomised trial comparing ECF with FAMTX in advanced oesophago-gastric cancer. *Proceedings of American Society of Clinical Oncology*. 15: Abs 1462.oral
61. Gore ME, Mainwaring PN, Macfarlane V, A'Hern R, Osborne R, Harper P, Quigley M, Slevin M, Jones A, Mansi JL, Blake P. (1996) A randomised study of high versus standard dose carboplatin in patients (PTS) with advanced epithelial ovarian cancer (EOC). *Proceedings of ASCO Abstr*: 769.oral
62. Gogas H, Lofts FJ, Evans TRJ, Millard FJC, Mansi JL. Combination of epirubicin and etoposide in the treatment of small cell lung cancer. Accepted 6th International Congress on Anti-Cancer Treatment 1996.poster
63. Gogas H, Mansi JL, Stubbs M, Howe FA, Griffiths JR. 31P spectroscopy of human breast tumours: A 3D chemical shift imaging study. *AACR, Washington* 1996 37: P205.poster
64. Lofts FJ, Gogas H, Evans TRJ, Millard FJC, Mansi JL. Out patient treatment with epirubicin and oral etoposide in the treatment of small cell lung cancer. *British Journal of Cancer* 1996 73: SXXVI P107.poster
65. Primrose, Bleiberg H, Daniel F, Johnson P, Mansi JL, Neoptolemos J, Seymour M, Van Belle S. A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced colorectal cancer. *Annals of Oncology* 1996 7 (Suppl 5): 159P.poster



66. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi JL, Findlay M, Hill A. A randomised trial comparing ECF with FAMTX in advanced oesophago-gastric cancer. *Annals of Oncology* 1996 7 (Suppl 5): 214P.poster
67. Evans TRJ, Mansi JL, Morgan DAL, Banham SW, Milroy R. A phase-2 study of vinorelbine in patients with advanced non-small cell lung cancer (NSCLC). *Annals of Oncology* 1996 7 (Suppl 5): 466P.poster
68. Gogas H, Mansi JL, Bliss J, Coombes RC. (1997) Can the presence of micrometastases (MM) in primary breast cancer (PBC) predict outcome? Long term (Median 12.5yrs) follow-up. *British Journal of Cancer* 76(1): 17 oral
69. Mainwaring PN, A'Hern RP, Macfarlane V, Slevin M, Harper P, Osborne R, Quigley M, Jones A, Mansi JL, Blake P, Wiltshaw E, Gore ME. (1997) A randomised trial of dose intensity in advanced epithelial ovarian cancer (EOC). *British Journal of Cancer* 76(1): 29.oral
70. Ahmed FY, Mainwaring PN, King DM, A'Hern RP, Ramsden M, McLaren B, Mansi JL, Harper P, Slevin M, Thomas H, Gore ME. (1997) A Phase II study of Epirubicin, Cisplatin and prolonged venous infusional 5-FU (ECF) in relapsed epithelial ovarian cancer (EOC). *British Journal of Cancer* 76(1): 29.oral
71. Webb A, Cunningham D, Scaffie JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi JL, Findlay M, Hill A. (1997) A randomised trial comparing ECF with FAMTX in advanced oesophageal gastric cancer – updated 2 year follow-up. *British Journal of Cancer* 76(1): 30.oral
72. Gogas H, Mansi JL, Bliss J, Gazet J-C, Berger U, Coombes RC. Can the presence of micrometastases in primary breast cancer (PBC) predict outcome? Long-term (median 12.5 years) follow-up. *BOA/ACP Meeting July 1997*.oral
73. O'Sullivan GJ, Mansi JL, Glees JP, Grundy A. Palliation of malignant dysphagia with expanding metallic stents. *British Journal of Cancer* (1997) 76(1): 35.poster
74. Gogas H, Mansi JL, Bliss J, Gazet J-C, Berger U, Coombes RC. Can the presence of micrometastases in primary breast cancer (PBC) predict outcome? Long-term (median 12.5 years) follow-up. *Proceedings of ASCO (1997) Abstr. 537*.poster
75. Gogas H, Mansi JL, Bliss J, Gazet J-C, Berger U, Coombes RC. Can the presence of micrometastases in primary breast cancer (PBC) predict outcome? Long-term (median 12.5 years) follow-up. *20th Annual San Antonio Breast Cancer Symposium, December 1997, Poster No537*.poster
76. Lofts FJ, Thompson F, Mansi JL. A phase I dose escalation of hydroxyurea in addition to continuous infusion 5-fluorouracil in patients with advanced colorectal cancer. *Poster*
77. Mitchell PLR, Al-Nasiri N, A'Hern R, Fisher C, Horwich A, Pinkerton CR, Shepherd JH, Gallagher C, Slevin M, Harper P, Osborne R, Mansi JL, Oliver T, Gore ME (1999) Treatment of nondysgerminomatous ovarian germ cell tumors - an analysis of 69 cases. *Poster – ASCO 1997*.
78. Last KW, Mansi JL, Oakley C, Lofts FJ. Long-term intravenous access devices: Superiority of peripherally inserted central cannulae (PICCs) over Hickman catheters (HCs). *ESMO (1998)*. oral
79. Fernando I, Eisenberg PD, Roshon S, Mansi J, Mills G, de Vries E. Evaluation of intratumoral cisplatin/epinephrine injectable gel for palliative treatment of metastatic breast cancer. *Proceedings of the NCI/EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, Netherlands, June 16-19, 1998* . oral

80. Fernando I, Eisenberg PD, Roshon S, Mansi J, Mills G, de Vries E. Intratumoral focused chemotherapy with cisplatin/epinephrine injectable gel for palliative treatment of metastatic breast cancer. For presentation at the 1st European Breast Cancer Conference Annual Meeting in Florence, Italy. September 29-October 3, 1998. *European Journal of Cancer* 34 (Supple 5): S21, 1998.oral
81. Smith IE, A'Hern, RP, Howell A, Hickish T, O'Brien M, Mansi J, Wilson C, Robinson A, Pratt W, Price C, Perren T, Laing R (2000). Preoperative continuous infusional EcisF (epirubicin, cisplatin and infusional 5FU) vs conventional AC chemotherapy for early breast cancer: A Phase III multicentre randomised trial by the Topic Trial Group. *Proceedings of the American Society of Clinical Oncology*, 19 (Abstract No 320), 84a.oral
82. Mansi, J, Bretherton-Watt D, Given-Wilson R, Thomas V, Carter N, Colston KW (2001) Polymorphisms in the Vitamin D Receptor Gene are Associated with Breast Cancer Risk. Poster/discussion - ASCO 2001.poster
83. Macdonald CD, Jayasundara SG, Mansi JL, Colston KW (2001). Inhibitory effects of bisphosphonates on growth of breast and lung carcinoma cells. *BACR/ACP*, 2001.poster
84. Senaratne SG, Oades GM, Pickering LM, Kirby RS, Mansi JL, Colston KW 2002. The bisphosphonate zoledronic acid induces apoptosis by impairing Ras membrane localisation and inducing cytochrome c release in breast and prostate cancer cells. *Proc Amer Ass Cancer Res Abs* 4311 poster
85. Evans J, Mansi et al. Angloceltic 2: AC versus AT as primary breast cancer. ASCO 2002 oral
86. Pickering LM, Senaratne SG, Mansi JL, Colston KW (2002). The bisphosphonate zoledronic acid upregulates apoptotic signals and impairs the adhesion of breast cancer cells to mineralised matrices prior to the induction of apoptosis. *British Journal of Cancer*, 86 (Suppl 1), S34-S121 (Abstract P161).poster
87. Pickering LM, Senaratne SG, Mansi JL, Colston KW (2002). The bisphosphonate zoledronic acid downregulates signalling through Ras effector pathways in human breast cancer cell lines. *San Antonio Breast Cancer Symposium. Br Cancer Res Treat* 76 S95. poster
88. Guy M, Lowe LC, Oades G, Bretherton-Watt D, Mansi JL, Coston KW. (2002). Approaches to evaluating the role of vitamin D receptor polymorphisms in breast and prostatic carcinoma. *British Endocrine Society, 21st Joint Meeting*, Harrogate, April 2002.poster
89. Guy M, Lowe LC, Mansi JL, Given-Wilson R, Thomas V, & Colston KW (2003). Association of vitamin D receptor gene polymorphisms with breast cancer risk and progression. *British Journal of Cancer*, abstract supplement 1 88:S13. oral
90. Guy M, Lowe LC, Bretherton-Watt D, Mansi JL, Given-Wilson R, Thomas V & Colston KW. Association of vitamin D receptor gene polymorphisms with breast cancer risk. *AACR 94th Annual Meeting*, 2003.poster
91. LM Pickering, JL Mansi, KW Colston (2003). Adhesion of breast cancer cells to extracellular matrices is inhibited by zoledronic acid and enhanced by aberrant Ras signalling. *Proc Am Soc Clin Oncol*.22 abs 3468 poster
92. Pickering LM, Coxon JP, Mansi JL, Colston KW (2003). HER2 overexpression confers relative resistance to zoledronic acid in vitro. *Br J Cancer* 88, S14. oral
93. Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D. Zoledronic acid significantly improves pain scores in patients with skeletal metastases secondary to breast cancer – analysis of home versus hospital administration. ASCO 2003.poster

94. Guy M, Lowe LC, Mansi JL, Given-Wilson R, Thomas V & Colston KW. 2003 Vitamin D receptor polymorphisms: An association with breast cancer risk and progression. 12th Workshop on Vitamin D, Maastricht, poster.
95. Pickering L, Mansi JL, Colston KW. 2003 Breast cancer cell adhesion to mineralised matrices is enhanced by her2/neu amplification and aberrant Ras signalling. Br Cancer Res Treat 82, S136 (Abstract #559, poster)
96. Palmerieri C, Lam E, Mansi J, Madden P, Warner M, Gustafsson J-A, Coombes RC (2003) The expression of ER $\beta$  in human breast cancer and the relationship to response to endocrine therapy and survival. Br Cancer Res Treat Abstract #264, poster
97. Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D. Zometa® (zoledronic acid) in patients with skeletal metastases secondary to breast cancer – a study of home versus hospital administration. Submitted – EBCC March 2004.
98. Macdonald CD, Pickering LM, Mansi JL, Colston KW. 2004 Anti-tumour potential of bisphosphonates on human lung carcinoma cell lines. Bone 34 S66 Abs 33
99. Pickering LM, Macdonald CD, Mansi JL, Colston KW. 2004 Zoledronic acid inhibits adhesion of breast cancer cells to mineralised matrices in a caspase-dependent manner. Bone 34, S68. Abs 38
100. Evans TRJ, Yellowlees A, Foster L, Mansi JL. 2004 Adriamycin and Taxotere compared with Adriamycin and Cyclophosphamide as primary medical therapy in breast cancer. Am Soc Clin Oncol June
101. Pickering LM, Lowe LC, Ganguli SJ, Mansi JL, Colston KW. Anti-metastatic effects of the bisphosphonate ester apomine in breast cancer cell lines in vitro. Br Cancer Research Meeting June 2004
102. Macdonald CD, Pickering LM, Mansi JL and Colston KW. Bisphosphonates induce apoptosis and inhibit adhesion to mineralised bone matrix in human lung carcinoma cell lines. British Cancer research Meeting, Manchester, June 2004.
103. Pickering LM, Mansi JL and Colston KW. Breast cancer cell adhesion is inhibited by zoledronic acid but restored by caspase inhibition. Bone and Tooth Society Annual Meeting, Oxford, June 2004.
104. Macdonald CD, Pickering LM, Mansi JL and Colston KW. Bisphosphonates induce apoptosis and inhibit adhesion to mineralised matrix in lung carcinoma cell lines. Bone and Tooth Society Annual Meeting, Oxford, June 2004
105. Lowe LC, Guy M, Townsend K, Campbell MJ, Hewison M, Mansi JL, and Colston KW. Low 25hydroxyvitamin D3 levels and breast cancer risk in a UK Caucasian population. British Cancer Research Meeting, Manchester, June 2004.
106. Pickering LM, Lowe LC, Ganguli SJ, Mansi JL, and Colston KW. Anti-metastatic effects of the bisphosphonate ester apomine in breast cancer cell lines in vitro. British Cancer Research Meeting, Manchester, June 2004.
107. Macdonald CD, Pickering LM, Mansi JL, and Colston KW. Bisphosphonates induce apoptosis and inhibit adhesion to mineralised bone matrix in human lung carcinoma cell lines. British Cancer Research Meeting, Manchester, June 2004.
108. Pickering LM, MacDonald CD, Mansi JL, Colston KW. Bisphosphonates induce apoptosis and inhibit adhesion to mineralised matrix in breast and lung carcinoma cell lines. International Conference on Cancer-Induced Bone Disease, Bethesda, USA 2005
109. Macdonald CD, Pickering LM, Mansi JL, Colston KW. Bisphosphonates have anti-cancer effects in breast and lung carcinoma cell lines Bone and Tooth Society July 2005

110. Pickering LM, Macdonald CD, Mansi JL, Colston KW. Bisphosphonates induce apoptosis and inhibit adhesion to mineralised matrix in lung carcinoma cell lines World Lung Congress, Barcelona 2005
111. Evans T R Jeffry, Yellowlees Ann, Devine Irene, Earl Helena, Cameron David A, Hutcheon Andrew W, Coleman Robert E, Crown John, Leonard Robert C F, Mansi Janine L on behalf of the Anglo-Celtic Co-operative Oncology Group. To compare the disease-free (DFS) and overall survival (OS), at a median follow up of 80 months, of women with primary or locally advanced breast cancer randomised to receive either doxorubicin and cyclophosphamide (AC) or doxorubicin and docetaxel (AD) as primary chemotherapy. ASCO 2008.
112. Leonard R C, Adamson D, Anderson R, Ballinger R, Bertelli G, Coleman R E, Fallowfield L, McLinden M, Mansi J, Thomas G. The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. ASCO 2010 Abs 851640
113. S. Ghosh; M Van Hemelrijck; CD Holdridge; JF Gibson; PJ Ross; J Mansi; R Lal; PA Ellis; PG Harper; S Chowdhury . How accurate is clinician reporting of chemotherapy side-effects? A prospective study comparing clinician with patient-reported symptoms. ASCO 2010 Abs 48920